新华社赫尔辛基10月19日电（记者朱昊晨 徐谦）芬兰国家技术研究中心联合欧洲多国科研机构和企 业，在一项最新科研项目中发现多种具有抗炎和抗衰老功效的植物基新成分，为可持续护肤品开发提供 新方向。 由芬兰国家技术研究中心统筹实施的InnCoCells项目团队筛选了100多种植物提取物，评估其对20种与 皮肤炎症和衰老相关的生物标志物的影响，最终确定约25种具有开发潜力的候选成分。这些成分可来源 于温室中培育的植物，生物反应器中培养的植物细胞与组织，或经"变废为宝"再利用的农业副产物，兼 具功效性与环境可持续性。 在发现的多种活性物质中，最引人注目的是丹麦岩荠的细胞培养物提取物，其具有显著的抗炎、抗衰老 和抗菌活性；黄灯笼椒细胞培养物提取物能有效对抗有害皮肤细菌，甚至对超级细菌"耐甲氧西林金黄 色葡萄球菌"也有抑制作用，并在无皮肤刺激性的情况下展现出强抗衰老活性；罗勒毛状根提取物则显 示出抗胶原酶和抗透明质酸酶活性，有助于延缓皮肤老化、维持水分平衡。 项目团队表示，相关研究成果为新一代绿色可持续化妆品成分研发开辟了道路。目前，他们正探索商业 模式与合作机制，推动相关植物基成分尽快进入市场应用阶段。（完） ...

Group 1 - The core viewpoint of the news is that 开拓药业-B (09939) has seen a significant stock price increase of over 8% following the announcement of the completion of a long-term safety trial for its new tyrosinase inhibitor, KT-939, which is designed to inhibit melanin production [1][2] - KT-939 has successfully completed the enrollment of 130 participants in its human safety trial, demonstrating effective inhibition of tyrosinase and showcasing antioxidant and anti-inflammatory properties, which are advantageous for cosmetic efficacy and safety [1] - The company is preparing for the registration application of KT-939, aiming to submit it to the Chinese drug regulatory authority in the third quarter of next year, following positive results from multiple safety and toxicology assessments [1] Group 2 - KT-939 is positioned to become the first domestically developed whitening cosmetic ingredient approved in China, marking a significant milestone in achieving complete independent intellectual property rights in this field [2] - The approval of a similar tyrosinase inhibitor, Thiamidol, in November 2024, highlights the potential market opportunity for KT-939, as it could provide a new option for the domestic and global skin whitening cosmetic market [2]

Group 1: DNV Group in China - DNV Group considers China as one of its most important regions globally, with the Chinese market accounting for approximately 28% of DNV's global business [2] - DNV operates five companies in China, with DNV (China) Ltd. serving as the headquarters, providing inspection and consulting services for new shipbuilding and offshore units [4] - DNV has issued over 8,000 certificates globally, with more than 6,000 certificates issued in China, serving various industries including automotive, aerospace, energy, and food [5] Group 2: Future Developments and Innovations - DNV is involved in around 30 joint development projects annually in China, focusing on new ship types and transformation solutions, particularly in the LNG shipbuilding sector [6] - The company has seen a nearly 30% increase in employee numbers over the past five years and emphasizes the training of local talent [6] - DNV aims to leverage Shanghai's advantages to enhance research and development in artificial intelligence, digital solutions, and alternative fuel technologies [6] Group 3: L'Oréal's R&D Center in China - L'Oréal's R&D center in Shanghai has become the largest and most comprehensive globally, with over 400 scientists and 372 patent applications expected in 2024 [7][10] - The center focuses on providing solutions for skin issues and benefits from Shanghai's thriving e-commerce ecosystem and digitalization [10] - L'Oréal is committed to investing in China, recently partnering with Veminsyn to develop innovative bioactive ingredients and launching a skin health management innovation center [11]